Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248

Similar articles for PubMed (Select 20938098)

1.

Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.

Hahn JY, Song YB, Choi JH, Choi SH, Lee SY, Park HS, Hur SH, Lee S, Han KR, Rha SW, Cho BR, Park JS, Yoon J, Lim do S, Lee SH, Gwon HC; DATE Registry Investigators.

Circ J. 2010 Nov;74(11):2314-21. Epub 2010 Oct 2.

2.

Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry.

Sgueglia GA, Burzotta F, Trani C, Todaro D, Talarico GP, Niccoli G, Porto I, Leone AM, Coluccia V, Mazzari MA, Mongiardo R, Schiavoni G, Crea F.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):503-9. doi: 10.1002/ccd.22714.

PMID:
20602477
3.

Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.

Balbi M, Fedele M, Bezante GP, Brunelli C, Barsotti A.

J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):839-42. doi: 10.2459/JCM.0b013e328337d7e7. No abstract available.

PMID:
20216229
4.

Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.

Hong SJ, Kim MH, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS.

Catheter Cardiovasc Interv. 2010 Dec 1;76(7):924-33. doi: 10.1002/ccd.22369.

PMID:
20815045
5.

Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.

Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.

Coron Artery Dis. 2013 May;24(3):217-23. doi: 10.1097/MCA.0b013e32835c8f74.

PMID:
23425771
6.

Long-term clinical results and predictors of adverse outcomes after drug-eluting stent implantation for bifurcation lesions in a real-world practice: the COBIS (Coronary Bifurcation Stenting) registry.

Gwon HC, Choi SH, Song YB, Hahn JY, Jeong MH, Seong IW, Kim HS, Rha SW, Yang JY, Yoon JH, Tahk SJ, Seung KB, Jang Y, Park SJ.

Circ J. 2010 Nov;74(11):2322-8. Epub 2010 Sep 28.

7.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

8.

Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.

Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators.

JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013.

9.

Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.

Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J, Huber K.

Thromb Haemost. 2010 Dec;104(6):1211-8. doi: 10.1160/TH10-04-0218. Epub 2010 Oct 12.

PMID:
20941464
10.

Sirolimus versus paclitaxel coronary stents in clinical practice.

Millauer N, Jüni P, Hofmann A, Wandel S, Bhambhani A, Billinger M, Urwyler N, Wenaweser P, Hellige G, Räber L, Cook S, Vogel R, Togni M, Seiler C, Meier B, Windecker S.

Catheter Cardiovasc Interv. 2011 Jan 1;77(1):5-12. doi: 10.1002/ccd.22597.

PMID:
20506333
11.

Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.

Birkmeier KA, Kastrati A, Byrne RA, Holle H, Schulz S, Tiroch K, Kufner S, Massberg S, Laugwitz KL, Schömig A, Mehilli J.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):494-501. doi: 10.1002/ccd.22757.

PMID:
20824758
12.

Crush stenting with drug-eluting stents: relevance of coronary bifurcation lesion location on angiographic and clinical outcomes.

Chen SL, Zhang JJ, Ye F, Liu ZZ, Zhu ZS, Lin S, Tian NL, Fang WY, Chen YD, Sun XW, Wei M, Shan SJ, Kan J, Qian J, Yang S, Yuan ZB, Kwan TW, Hu DY.

Clin Cardiol. 2010 Dec;33(12):E32-9. doi: 10.1002/clc.20544. Epub 2010 Sep 20.

PMID:
20857513
13.

Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.

Rodriguez AE, Vigo CF, Delacasa A, Mieres J, Fernandez-Pereira C, Bernardi V, Bettinoti M, Rodriguez-Granillo AM, Rodriguez-Granillo G, Santaera O, Curotto V, Rubilar B, Tronge J, Palacios IF, Antoniucci D; EUCATAX Investigators.

Catheter Cardiovasc Interv. 2011 Feb 15;77(3):335-42. doi: 10.1002/ccd.22769. Epub 2010 Nov 30.

PMID:
20824769
14.

Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.

Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.

Circ Cardiovasc Interv. 2012 Jun;5(3):372-80. doi: 10.1161/CIRCINTERVENTIONS.111.967257. Epub 2012 Jun 5.

15.

Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.

Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F; MATRIX Study Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):408-16. doi: 10.1002/ccd.23223. Epub 2011 Nov 9.

PMID:
21735531
16.

Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.

Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ; KAMIR Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):936-45. doi: 10.1016/j.jcin.2012.05.009.

17.

Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry.

Manari A, Ortolani P, Guastaroba P, Marzaroli P, Menozzi M, Magnavacchi P, Varani E, Vignali L, Campo G, Marzocchi A.

J Cardiovasc Med (Hagerstown). 2011 Feb;12(2):102-9. doi: 10.2459/JCM.0b013e32833e58e4.

PMID:
20814313
18.

Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.

Brown RA, Williams M, Barker CM, Mauri L, Meredith IT, Fajadet J, Wijns W, Leon MB, Kandzari DE.

Catheter Cardiovasc Interv. 2010 Nov 15;76(6):804-13. doi: 10.1002/ccd.22624. Epub 2010 Sep 2.

PMID:
20815043
19.

Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.

Nishihira K, Shibata Y, Ishikawa T, Nomura K, Nakama T, Mine D, Inoue Y, Ashikaga K, Kuriyama N, Matsuyama A, Imamura T, Asada Y, Kitamura K.

Circ J. 2010 Nov;74(11):2329-33. Epub 2010 Sep 28.

20.

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.

Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schömig A, Kastrati A.

Thromb Haemost. 2010 Sep;104(3):626-32. doi: 10.1160/TH09-11-0800. Epub 2010 Jul 20.

PMID:
20664905
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk